Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

A new class of drugs has become a phenomenon. GLP-1 receptor agonists, originally developed to treat type 2 diabetes, are now ...

Compelling new ARD-201 preclinical data informs optimized Phase 2 clinical development strategy of obesity programs: Phase 2 POWER trial of oral ARD-201 to focus on weight rebound in patients ...

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 ...